Hematopoietic Stem Cell Transplantation
📧 Sign up to get email alerts when something new happens for Hematopoietic Stem Cell Transplantation.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Nivestim (filgrastim) — Pfizer Europe MA EEIG
Nivestim (filgrastim) has been authorised by EMA for hematopoietic stem cell transplantation and cancer indications.
-
EMA approval · 2026-07-22EMA Authorised: Plerixafor Accord (Plerixafor) — Accord Healthcare S.L.U.
The EMA authorises Plerixafor Accord for use in multiple myeloma and hematopoietic stem cell transplantation with Accord Healthcare S.L.U. a…
-
EMA approval · 2026-07-16EMA Authorised: Zemcelpro (allogeneic umbilical cord-derived CD34- cells, non-expanded;dorocubicel) — Cordex Biologics International Limited
EMA has authorised Zemcelpro (allogeneic umbilical cord-derived CD34- cells, non-expanded; dorocubicel) for hematologic neoplasms and hemato…
-
EMA approval · 2026-07-14EMA Authorised: Zefylti (filgrastim) — CuraTeQ Biologics (Malta) Limited
Zefylti (filgrastim) has been authorised by EMA for use in neutropenia, hematopoietic stem cell transplantation, and cancer indications.
-
EMA approval · 2026-06-05EMA Authorised: Zarzio (filgrastim) — Sandoz GmbH
Authorised status for Zarzio (filgrastim) by Sandoz GmbH in the EU, covering hematopoietic stem cell transplantation and cancer indications.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-09-29EMA Authorised: Zefylti (filgrastim) — CuraTeQ Biologics s.r.o
The European Medicines Agency authorised Zefylti (filgrastim) as a biosimilar for neutropenia, hematopoietic stem cell transplantation, and …
-
EMA approval · 2025-07-08EMA Authorised: Zarzio (filgrastim) — Sandoz GmbH
The EMA authorised Zarzio, a filgrastim biosimilar from Sandoz GmbH, for use in hematopoietic stem cell transplantation and cancer indicatio…